IC
PTHS

Ikarian Capital’s Pelthos Therapeutics PTHS Stock Holding History

Ikarian Capital’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.39M Buy
256,598
+840
+0.3% +$19.9K 0.44% 57
2025
Q4 		$7.93M Buy
255,758
+193,307
+310% +$5.58M 0.62% 47
2025
Q3 		$1.75M Buy
+62,451
New +$1.52M 0.18% 105
2025
Q2 		– Sell
-44,085
Closed -$626K – 193
2025
Q1 		$626K Buy
+44,085
New +$755K 0.08% 108

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Ikarian Capital's PTHS Position: Q1 2026 in Review

Ikarian Capital increased its Pelthos Therapeutics (PTHS) stake by 0.33% in Q1 2026, buying an estimated $19.9K and bringing the position to 256,598 shares worth $5.39M. The position accounts for 0.44% of the portfolio, ranked #57.

Ikarian Capital first reported a position in PTHS in Q1 2025 and has held it in 4 quarters since. The position peaked at $7.93M in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Ikarian Capital held 256,598 shares of Pelthos Therapeutics worth $5.39M as of Q1 2026.
  • Ikarian Capital bought 840 Pelthos Therapeutics shares in Q1 2026, an estimated $19.9K.
  • Pelthos Therapeutics made up 0.44% of Ikarian Capital's portfolio in Q1 2026, its #57 holding.
  • Ikarian Capital first reported a position in Pelthos Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Ikarian Capital's Pelthos Therapeutics position peaked at $7.93M in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.